What baseline laboratory panels (including normal and critical ranges, rationale, collection methods, frequency, trend monitoring relative to interventions, and clinical significance of abnormal values), diagnostic imaging studies, invasive monitoring modalities, and bedside neurological tests should be obtained for an acute neurological evaluation?

Acute Neurological Evaluation: Laboratory, Diagnostic, and Monitoring Framework

Baseline Laboratory Panels

All patients with suspected acute neurological emergencies require immediate blood work that should not delay imaging or acute treatment decisions. 1

Essential Initial Laboratory Tests

Core panel (obtain immediately): 1

• Electrolytes - Critical for identifying metabolic derangements that mimic stroke
• Random glucose - Hypoglycemia can present with focal neurological deficits mimicking stroke; hyperglycemia associated with worse outcomes
• Complete blood count (CBC) - Assess for thrombocytopenia, anemia, infection
• Coagulation studies (INR, aPTT) - Essential before thrombolytic therapy; elevated INR requires reversal in hemorrhagic stroke
• Creatinine and eGFR - Renal function assessment, though should not delay CTA in most patients ("neurons over nephrons" principle) 1
• Troponin - Acute stroke and myocardial infarction can occur contemporaneously 1

Normal and Critical Ranges - Key Considerations

Critical values requiring immediate notification: 2

• Glucose <50 mg/dL or >400 mg/dL
• Sodium <120 mEq/L or >160 mEq/L
• Platelet count <50,000/μL
• INR >5.0 (especially in hemorrhagic stroke)
• Creatinine >4.0 mg/dL (acute change)

Important caveat: Standard reference ranges derived from healthy adults may not apply to ICU populations. ICU patients' laboratory distributions differ significantly from standard ranges (mean overlapping coefficient 0.51), and both best and worst outcome groups show marked divergence from reference ranges. 3 This means minor variations labeled as "abnormal" may not be clinically significant in critically ill neurological patients. 4, 3

Collection and Timing Considerations

Critical timing principle: Blood work should be obtained immediately but must not delay imaging or treatment initiation for intravenous thrombolysis or endovascular therapy. 1 The only exceptions are: 1

• Clinical suspicion of bleeding abnormality or thrombocytopenia
• Patient on warfarin (INR required)
• Patient on heparin or novel anticoagulants
• Unknown anticoagulation status

For patients on warfarin with ICH: INR results are mandatory and reversal with prothrombin complex concentrate (PCC) plus vitamin K should be initiated immediately. 1

Frequency and Trend Monitoring

Serial monitoring requirements: 1

• Cardiac biomarkers: Repeat if initial presentation suggests cardiac involvement or if clinical deterioration occurs 1
• Coagulation studies: Every 6-12 hours if actively reversing anticoagulation in hemorrhagic stroke 1
• Glucose: Every 4-6 hours initially, then per protocol based on glycemic control 5
• Electrolytes: Daily minimum, more frequently if abnormal or receiving IV fluids

Clinical Significance of Abnormal Values

Glucose abnormalities: 1

• Hypoglycemia (<70 mg/dL): Can mimic stroke with focal deficits - requires immediate correction
• Hyperglycemia (>180 mg/dL): Associated with cerebral edema, hemorrhagic transformation, and worse outcomes in ischemic stroke

Coagulation abnormalities: 1

• Elevated INR (>1.7): Contraindication to thrombolysis; in hemorrhagic stroke, requires immediate reversal
• Thrombocytopenia (<100,000/μL): Increases hemorrhage risk; <50,000/μL is contraindication to thrombolysis

Troponin elevation: Indicates concurrent myocardial ischemia or neurogenic cardiac injury from stroke itself. 1 Both require cardiac monitoring and may influence acute management decisions.

Renal dysfunction: While important for contrast decisions, should not delay CTA in patients with disabling acute stroke symptoms unless severe known renal impairment exists. 1

Diagnostic Imaging Studies

Immediate brain imaging is mandatory for all suspected acute stroke patients. 1

Primary Imaging Modality

Non-contrast CT (NCCT) is the first-line imaging for most institutions because it: 1

• Definitively excludes hemorrhage
• Is rapidly available
• Identifies stroke mimics (tumor, abscess)
• Detects early ischemic changes
• Is cost-effective primarily through hemorrhage detection

MRI with diffusion-weighted imaging (DWI): More sensitive than CT for acute infarction (88-100% sensitivity) but not routinely cost-effective for all patients. 1 Reserve for: 1

• Puzzling clinical presentations
• Uncertain stroke localization
• Posterior circulation symptoms where CT sensitivity is lower
• When NCCT is negative but clinical suspicion remains high

Vascular Imaging

CT angiography (CTA) or MR angiography (MRA): 1

• Essential for institutions providing endovascular therapy
• Identifies large vessel occlusion for thrombectomy eligibility
• Should not delay treatment in patients presenting <3 hours from onset 1
• In hemorrhagic stroke, recommended to exclude aneurysm or arteriovenous malformation 1

Timing relative to intervention: Vascular imaging is necessary before intra-arterial therapy but should not delay intravenous thrombolysis in the 0-3 hour window. 1

Invasive Monitoring Modalities

Multimodality monitoring (MMM) is routinely performed in neurocritical care units for patients whose clinical examination is limited by sedation, coma, or disease severity. 1

Intracranial Pressure (ICP) Monitoring

Indications in acute neurological emergencies: 1

• Hemorrhagic stroke with clinical signs of increased ICP
• Large ischemic stroke with mass effect
• Glasgow Coma Scale (GCS) ≤8 with suspected elevated ICP
• Deteriorating neurological status despite medical management

Target ICP: <20 mmHg in most cases 1

Continuous EEG Monitoring

Consider in: 1

• Neonates and children with stroke (seizures common presentation)
• Adults with unexplained reduced level of consciousness
• New-onset refractory status epilepticus (NORSE)
• Suspected autoimmune encephalitis with altered mental status 1

Important principle: A single self-limiting seizure at stroke onset should not be treated with long-term anticonvulsants. 1 Only recurrent seizures require ongoing treatment.

Cardiac Monitoring

All acute stroke patients require: 1

• 12-lead ECG on arrival (can be deferred until after thrombolysis decision if hemodynamically stable) 1
• Continuous telemetry for at least 24-48 hours to detect paroxysmal atrial fibrillation or serious arrhythmias 1
• Serial ECGs if cardiac ischemia suspected

Bedside Neurological Tests

Standardized Stroke Scales

The National Institutes of Health Stroke Scale (NIHSS) is the recommended standardized assessment tool. 1 It should be: 1

• Performed on all awake or drowsy patients
• Completed rapidly (typically 5-10 minutes)
• Used to quantify baseline severity
• Repeated to track clinical changes
• Used to identify thrombolysis/thrombectomy candidates
• Recognized as strong predictor of outcomes and hemorrhage risk

For obtunded/comatose patients: Use Glasgow Coma Scale (GCS) instead. 1

Vital Signs Monitoring

Acute phase assessment must include: 1

• Heart rate and rhythm - continuous monitoring
• Blood pressure - every 15 minutes until stable in hemorrhagic stroke 1; specific targets based on thrombolysis eligibility in ischemic stroke
• Temperature - fever worsens outcomes
• Oxygen saturation - maintain >94%
• Hydration status - assess volume status
• Seizure activity - continuous observation

Blood pressure targets in ischemic stroke: 1

• For thrombolysis candidates: Must reduce to <185/110 mmHg before treatment
• For non-candidates: Only treat if SBP >220 mmHg or DBP >120 mmHg
• Aggressive lowering may worsen ischemia by decreasing perfusion pressure

Blood pressure in hemorrhagic stroke: Target SBP <140 mmHg is safe, though optimal targets remain under investigation. 1 Monitor every 15 minutes initially, then every 30-60 minutes for first 24-48 hours.

Swallowing Screen

Must be completed before any oral intake using a validated screening tool. 1

• Perform as early as possible, ideally within 24 hours
• Should not delay acute stroke treatment decisions
• Patients remain NPO until screen completed
• Oral medications withheld until normal swallow confirmed
• Use alternate routes (IV, rectal) while NPO 1

Special Diagnostic Considerations for Autoimmune Encephalitis

When autoimmune encephalitis is suspected: 1

• Lumbar puncture: Test CSF for oligoclonal bands, IgG index, IgG synthesis rate, and neuronal autoantibodies
• Serum autoantibodies: Send simultaneously with CSF testing
• Brain FDG-PET: Consider when clinical suspicion high but other studies uninformative
• Cancer screening: CT chest/abdomen/pelvis with contrast; consider mammogram, pelvic ultrasound, whole-body FDG-PET based on antibody profile and risk factors

Do not delay immunotherapy while awaiting antibody results if infection ruled out and clinical suspicion is high. 1

Common Pitfalls to Avoid

1. Never delay imaging or thrombolysis waiting for laboratory results unless specific contraindications exist (known anticoagulation, suspected bleeding disorder). 1

2. Do not withhold CTA for renal function results in patients with disabling acute stroke symptoms - "neurons over nephrons." 1

3. Avoid treating single self-limiting seizures at stroke onset with long-term anticonvulsants. 1

4. Do not interpret ICU laboratory values using standard reference ranges - critically ill patients have different distributions that may not indicate pathology. 4, 3

5. Chest X-ray should not delay acute stroke treatment - defer until after thrombolysis decision unless hemodynamically unstable. 1

6. Recognize that troponin elevation may be neurogenic from stroke itself, not necessarily indicating primary cardiac event. 1